MPS World Summit 2026
Walter E. Washington Convention Center, Washington, DC
May 26, 2026 - May 29, 2026The MPS World Summit gathers a global community of researchers, innovators, and regulatory experts advancing next‑generation microphysiological systems and organ‑on‑chip technologies. Join us at the event and attend our presentation and poster sessions to learn about our patient-derived organoid models and HepatoXcell™ primary human hepatocytes.
Want to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.
Attend our Presentation
Beyond animal models: Precision oncology begins with human-derived 3-D models
Join our presentation to explore how patient-derived cancer organoids from the HCMI are advancing precision oncology by capturing tumor complexity, heterogeneity, and clinically relevant drug responses. Learn how these well-characterized, data-rich models are enabling predictive drug testing, biomarker discovery, and more inclusive cancer research.
Presenter: Carolina Lucchesi, PhD, Principal Scientist, ATCC
Date & time: Wednesday, May 27, 2026, from 12:45–1:45 PM
Location: Room CC 203B
Explore our featured products
Organoids
During the drug discovery process, having access to models that recapitulate tumor properties is essential for predictive screening. ATCC provides patient-derived 3-D organoid models annotated with molecular and clinical data that represent a variety of healthy and cancerous tissues. These next-generation cancer models are capable of long-term expansion in culture while remaining phenotypically and genetically stable.
Explore patient-derived organoidsOrganoid Growth Kits
In efforts to simplify organoid culture, ATCC has developed Organoid Growth Kits, which comprise single-use supplements created to streamline media preparation. These kits contain the most costly and cumbersome supplements and reagents, reducing the time and effort required to prepare media and ensuring the successful growth of your organoids.
Explore organoid growth kits
Primary human hepatocytes are considered the gold standard for in vitro liver models due to their high predictive value in drug metabolism and toxicity studies. They can provide early insights into how a drug will behave in the human body, potentially reducing the risk of adverse effects in clinical trials. ATCC hepatocytes are meticulously isolated and characterized to ensure the highest quality and performance for your drug development and toxicity testing needs. Try our HepatoXcell™ primary human hepatocytes and media today!
Learn moreCheck out our resources
Exploring the performance of HepatoXcell in a variety of culture formats
In this application note, we demonstrate that the HepatoXcell™ system supports diverse culture formats, offering flexibility for tailoring experimental setups for liver biology research, disease modeling, drug discovery, and toxicity testing.
More
Brochure
Human Cancer Models Initiative (HCMI)
ATCC offers a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues
MorePrimary Human Hepatocytes
Discover how HepatoXcell™ can support your predictive drug development and toxicity testing.
MoreContact us today
Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care. Please complete our form to let us know how we can help, and we will start working on your needs right away.
